Pharmacy benefit managers inflated drug prices by $7.3B

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
UnitedHealth CEO Blames Drug Companies, Not Pharmacy Benefit Managers, For High Prices
Pharmacy benefit managers actually "play a vital role in holding" sometimes-inflated prices down, said UHG CEO Andrew Witty in an earnings call.
Pharmacy owner reacts to FTC report showing billions made from inflated drug prices
Strawberry Hills Pharmacy owner Daniel Jones reacted Thursday to a recent Federal Trade Commission report which showed pharmacy benefit managers made billions of dollars by inflating the price of drugs.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
The American Journal of Managed Care2h
Insurer-PBM Firms Dominate Medicare Part D Market, Steering Patients to Their Pharmacies
Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...
Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Arkansas lawmakers introduce new bill aimed at removing PBM's pharmacy license
Pharmacy advocate groups are teaming up with lawmakers to get new legislation passed to stop monopolistic behaviors from ...
New legislation aims to prevent PBMs from controlling drug pricing and pharmacy ownership
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...